Skip to main content
. Author manuscript; available in PMC: 2023 Jul 6.
Published in final edited form as: Acta Neuropathol. 2023 Feb 2;145(4):501–503. doi: 10.1007/s00401-023-02543-7

Fig. 1.

Fig. 1

CDKN2A/B heterozygous loss shortens RFS. a CDKN2A/B scoring based on copy number counts of CNV traces. b Oncoprint of the 659 tumors with clinical data, clustered by molecular Groups. The asterisk marks the nonrecurrent tumor that had CDK2A/B loss. c Median RFS by molecular group and CDKN2A/B status within Group C, omitting two unclassifiable tumors and the nonrecurrent group A tumor. mRFS in months of each group in parenthesis. Kruskal–Wallis ANOVA by group as well as genotype